期刊文献+

清肝化瘀方含药血清对肝癌细胞的影响 被引量:2

SERAPHARMACOLOGICAL EFFECTS OF LIVER- CLEARING AND STASIS-REMOVING ON HUMAN HEPATOCELLULAR CARCINOMA CELL
下载PDF
导出
摘要 目的观察原发性肝癌(primary liver cancer,PLC)患者和健康志愿者清肝化瘀方含药血清对肝癌细胞SMMC-7721增殖、细胞凋亡、细胞周期的影响。方法采用四唑盐比色法[3-(4,5-dimethy-2 thiahiazoyl)-3,5-di-phenyl-tetrazolium bromide,MTT]法、流式细胞术比较PLC患者及健康志愿者服用清肝化瘀方药前后,含药血清对人肝癌细胞SMMC-7721增殖的抑制作用。结果培养48h,PLC患者清肝化瘀方含药血清对SMMC-7721细胞生长的抑制作用最明显,上调bax基因表达,下调bcl-2表达(P<0.05)。健康志愿者服药前后的血清对SMMC-7721细胞的生长均有抑制作用,但差异无统计学意义(P>0.05)。结论 PLC患者服用清肝化瘀方后的含药血清可显著抑制SMMC-7721细胞增殖并促进其凋亡。 Objective To investigate the serapharmacological effects of liver-clearing and stasis-removing on proliferation,apoptosis and cellular cycling of SMMC-7721 cell.Methods MTT and flow cytometry assay were used to compare the different effects between primary liver cancer (PLC) patients'and volunteers'serum on proliferation,apoptosis and cellular cycling of SMMC-7721 cell before and after liver-clearing and stasis-removing was administrated.Results The inhibitory effect of patient's serum on the proliferation of SMMC-7721 cell was the most significant in48h (P <0.01).And it could up-regulate the expression of bax gene and down-regulate the expression of bcl-2 gene.But the healthy volunteers'serum before and after liver-clearing and stasis-removing administration showed no significant inhibitory effect on SMMC-7721 proliferation.Conclusion The serum of PLC patients taken liver-clearing and stasis-removing could inhibit SMMC-7721 cell's proliferation.
出处 《河北医科大学学报》 CAS 2011年第5期501-504,共4页 Journal of Hebei Medical University
基金 河北省自然科学基金资助项目(303516)
关键词 清肝化瘀方 血清 肝肿瘤 liver-clearing and stasis-removing serum liver neoplasms
  • 引文网络
  • 相关文献

参考文献5

二级参考文献46

  • 1詹金锴,熊宗胜,戴风君,徐祖豫.脊髓损伤排尿功能障碍的早期康复措施[J].现代康复,1998,2(10):1082-1083. 被引量:3
  • 2王效民,汤钊猷,薛琼,邹合强,鲍卫华,洪雪莺.转化生长因子α及其受体促进肝癌细胞生长[J].中国肿瘤临床,1995,22(3):153-156. 被引量:10
  • 3Cun-Liang Deng,Xin-Wen song,Hai-Jun Liang,Chen Feng,Yun-Jian Sheng,Ming-Yong Wang.Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells[J].World Journal of Gastroenterology,2006,12(11):1752-1756. 被引量:26
  • 4王宁生.关于血清药理学的若干思考[J].中国中西医结合杂志,1999,19(5):263-263.
  • 5R.J.Krane.临床神经泌尿学[M].北京:人民卫生出版社,1984.149-150.
  • 6服部孝道.神经原性膀胱的诊断和治疗[M].海口:海南人民出版社,1989.120-144.
  • 7[1]Festi D,Colecchia A,Sacco T,Bondi M,Roda E,Marchesini G.Hepatic steatosis in obese patients:clinical aspects and prognostic significance.Obes Rev 2004; 5:27-42
  • 8[2]Browning JD,Horton JD.Molecular mediators of hepatic steatosis and liver injury.J Clin Invest 2004; 114:147-152
  • 9[3]Dam-Larsen S,Franzmann M,Andersen IB,Christoffersen P,Jensen LB,Sorensen TI,Becker U,Bendtsen F.Long term prognosis of fatty liver:risk of chronic liver disease and death.Gut 2004; 53:750-755
  • 10[4]James O,Day C.Non-alcoholic steatohepatitis:another disease of affluence.Lancet 1999; 353:1634 -1636

共引文献97

同被引文献34

引证文献2

二级引证文献19

;
使用帮助 返回顶部